Status:
RECRUITING
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Lead Sponsor:
Gangnam Severance Hospital
Collaborating Sponsors:
Seoul National University
Conditions:
Breast Cancer
Estrogen Receptor Positive Tumor
Eligibility:
FEMALE
20-50 years
Phase:
PHASE4
Brief Summary
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian func...
Detailed Description
* Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). * In these, ovarian f...
Eligibility Criteria
Inclusion
- ER+HER2- breast cancer
- Premenopausal and age \<=50
- T1 or T2
- N1 including micrometastasis
- Genomic Low Risk by OncoFREE test® (1-20)
Exclusion
- Postmenopausal women
- ER-negative breast cancer
Key Trial Info
Start Date :
February 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2033
Estimated Enrollment :
418 Patients enrolled
Trial Details
Trial ID
NCT05333328
Start Date
February 6 2023
End Date
January 1 2033
Last Update
May 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, Korea, South Korea, 06229
2
Seoul National University Hospital
Seoul, South Korea